Talk Data Science, RWE & Artificial Intelligence track
S0302 - AI in the Medicines Lifecycle: Accelerating Innovation. Part 2: A Global Perspective
Tue, Mar 18, 2025 · 3:10–4:20 PM CET San Francisco Room, Congress Center Basel
About this session
What are the real-world applications of AI in the drug development lifecycle? This session will delve into the practical use of AI in various phases of drug development, highlighting specific use cases and examples rather than hypothetical possibilities. Discussions will cover emerging regulations and collaborative initiatives among global regulators, current and potential applications of AI in the medicinal product lifecycle, and the challenges of navigating regulatory landscapes. Additionally, the session will consider multi-stakeholder approaches to AI-supported regulatory processes and explore the broader implications of AI in medicines development.
Programme:
- Panel Discussion — Luis Pinheiro, Nicolas Loeffler-Perez, Alison Cave
- 4. TRICIA: Leveraging NLP to Enhance Risk Assessment of Incoming Incident Reports — Nicolas Loeffler-Perez
- 1. Introduction and Scene Setting — Alison Bond
- 5. Take 5 & Closing — Alison Bond
- 3. Navigating Regulatory Landscapes: AI in Life Sciences Drug Development and Compliance Challenges — Sam Laermans
- 2. AI in Regulatory Intelligence and Strategy A case study — Michail Doulis
Speakers
-
Global AI Lead & Director · NNIT
Speaker
-
Senior Epidemiology Expert, RWE, Data Analytics and Methods Taskforce · European Medicines Agency
Panelist
-
Chief Safety Officer · Medicines and Healthcare Products Regulatory Agency (MHRA)
Panelist
